- Clinical Stem Cell Services
- GMP iPSC/MSC MCB Manufacturing – Histocell (Europe Partner Overview)
Clinical Stem Cell Services
Histocell – our GMP iPSC and MSC Manufacturing Partner in Europe

Located in Bilbao, Spain, Histocell is a CDMO and a clinical-stage biopharmaceutical company that specializes in developing cell therapy products for regenerative medicine.
Histocell's highly reliable and qualified scientific team has more than 20 years of experience. They will take care of your iPSC or MSC cell therapy needs with a flexible and scalable manufacturing process.
In our GMP stem cell services partnership:
- Histocell manufactures investigational medicinal products for human use for European, US, and Japanese customers.
- Histocell also provides all regulatory safety and quality controls specified by regulatory authorities and all additional required documentary support for the cells.
Authorized GMP facility for Manufacturing Clinical Grade Products
Histocell's newly built 800 m2 GMP facility is already authorized and registered by the European Union Manufacturer Authorization (EMA) for the manufacturing of clinical grade cells in compliance with the GMP guidelines of EMA Regulation (EU) 2017/1569.
Advanced Therapy Medicinal Products (ATMPs) Manufacturing
Since 2011, Histocell has been an authorized provider of GMP ATMPs manufacturing services to clients around the world.
Around 300 patients have already been treated with ATMPs manufactured by Histocell, and more than 350 batches have been manufactured under GMP.
Advanced Therapy Cell Production Facilities
Histocell's new Advanced Therapies GMP cell production unit has 800 m2 of capacity.
- GMP manufacturing suites and associated infrastructure
- Fully equipped to manufacture both autologous and allogeneic therapies
- Manufacturing and storage for cell therapy stocks (MCB, WCB)
- Production and characterization of cell-derived biologics such as secretomes and exosomes
- Manufacturing capability: approx. 1200 batches/year
- Designed to support both pre-clinical and clinical phases
- Histocell is also gearing up to support commercial manufacturing
Services We Offer In Partnership With Histocell
Working together, REPROCELL and Histocell are well placed to support your GMP stem cell manufacturing project.
Ask our experts about our GMP services
Discover more
Resources
- FAQ: Clinical iPSCs
- FAQ: Clinical MSCs
- FAQ: iPSC-Derived Exosomes
- Making iPSC-Derived Therapeutics a Clinical Reality – our external article in the European Biopharmaceutical Review.
Gene Editing Services
On the REPROCELL blog
Latest in Stem Cells
REPROCELL Attends Japan-Maryland Night 2026
REPROCELL was honored to attend Japan-Maryland Night on Wednesday March 4th 2026 Maryland State, USA, hosted by the Embassy of Japan (in Washington DC).
06 March 2026
From StemRNA™ Clinical Seed Clone to GMP-Ready Cell Therapy Programs
Discover how REPROCELL’s StemRNA™ Clinical iPSC Seed Clones streamline the path to GMP-ready cell therapy, simplifying regulatory processes and enabling scalable, high-quality manufacturing.
27 February 2026
iPSC-, MSC- and iMSC-Derived Exosome Therapeutics: The Cell-Free Future of Regenerative Medicine
Explore the future of regenerative medicine with iPSC-, MSC-, and iMSC-derived exosome therapeutics, focusing on their advantages, challenges, and clinical potential.
19 November 2025




